Works matching AU Wainberg, Zev A

Results: 67
    1

    A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

    Published in:
    2017
    By:
    • Wainberg, Zev;
    • Alsina, Maria;
    • Soares, Heloisa;
    • Braña, Irene;
    • Britten, Carolyn;
    • Conte, Gianluca;
    • Ezeh, Patrick;
    • Houk, Brett;
    • Kern, Kenneth;
    • Leong, Stephen;
    • Pathan, Nuzhat;
    • Pierce, Kristen;
    • Siu, Lillian;
    • Vermette, Jennifer;
    • Tabernero, Josep;
    • Wainberg, Zev A;
    • Soares, Heloisa P;
    • Braña, Irene;
    • Britten, Carolyn D;
    • Del Conte, Gianluca
    Publication type:
    journal article
    2
    3

    Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.

    Published in:
    Journal of Hematology & Oncology, 2025, v. 18, n. 1, p. 1, doi. 10.1186/s13045-025-01705-2
    By:
    • Ouyang, Quchang;
    • Rodon, Jordi;
    • Liang, Yan;
    • Wu, Xinhong;
    • Li, Qun;
    • Song, Lihua;
    • Yan, Min;
    • Tong, Zhongsheng;
    • Liu, YunPeng;
    • Wainberg, Zev A.;
    • Wang, Ying;
    • Geng, Cuizhi;
    • Ulahannan, Susanna V.;
    • Yu, Guohua;
    • Sharma, Manish R.;
    • Wang, Xiang;
    • Wang, Judy S.;
    • Spira, Alexander;
    • Zhao, Weihong;
    • Sanborn, Rachel E.
    Publication type:
    Article
    4

    Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103).

    Published in:
    Journal of Clinical Pharmacology, 2024, v. 64, n. 5, p. 544, doi. 10.1002/jcph.2397
    By:
    • Garralda, Elena;
    • Oh, Do Youn;
    • Italiano, Antoine;
    • Bedard, Philippe L.;
    • Delord, Jean‐Pierre;
    • Calvo, Emiliano;
    • LoRusso, Patricia;
    • Wainberg, Zev;
    • Cervantes, Andres;
    • Rodriguez‐Vida, Alejo;
    • Shemesh, Colby S.;
    • Sane, Rucha;
    • Mendus, Diana;
    • Ding, Hao;
    • Hendricks, Robert;
    • Meng, Ray;
    • Cho, Byoung Chul;
    • Kim, Tae Won;
    • Wu, Benjamin
    Publication type:
    Article
    5
    6
    7
    8

    Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

    Published in:
    Gastric Cancer, 2019, v. 22, n. 4, p. 828, doi. 10.1007/s10120-018-00909-5
    By:
    • Bang, Yung-Jue;
    • Kang, Yoon-Koo;
    • Catenacci, Daniel V.;
    • Muro, Kei;
    • Fuchs, Charles S.;
    • Geva, Ravit;
    • Hara, Hiroki;
    • Golan, Talia;
    • Garrido, Marcelo;
    • Jalal, Shadia I.;
    • Borg, Christophe;
    • Doi, Toshihiko;
    • Yoon, Harry H.;
    • Savage, Mary J.;
    • Wang, Jiangdian;
    • Dalal, Rita P.;
    • Shah, Sukrut;
    • Wainberg, Zev A.;
    • Chung, Hyun Cheol
    Publication type:
    Article
    9
    10

    Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

    Published in:
    PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0054014
    By:
    • Shah, Manish A.;
    • Wainberg, Zev A.;
    • Catenacci, Daniel V. T.;
    • Hochster, Howard S.;
    • Ford, James;
    • Kunz, Pamela;
    • Lee, Fa-Chyi;
    • Kallender, Howard;
    • Cecchi, Fabiola;
    • Rabe, Daniel C.;
    • Keer, Harold;
    • Martin, Anne-Marie;
    • Liu, Yuan;
    • Gagnon, Robert;
    • Bonate, Peter;
    • Liu, Li;
    • Gilmer, Tona;
    • Bottaro, Donald P.
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.

    Published in:
    Cancers, 2024, v. 16, n. 7, p. 1323, doi. 10.3390/cancers16071323
    By:
    • Gardner, Faithlore P.;
    • Wainberg, Zev A.;
    • Fountzilas, Christos;
    • Bahary, Nathan;
    • Womack, Mark S.;
    • Macarulla, Teresa;
    • Garrido-Laguna, Ignacio;
    • Peterson, Patrick M.;
    • Borazanci, Erkut;
    • Johnson, Melissa;
    • Ceccarelli, Matteo;
    • Pelzer, Uwe
    Publication type:
    Article
    25

    Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.

    Published in:
    2021
    By:
    • Gelderblom, Hans;
    • Wagner, Andrew J.;
    • Tap, William D.;
    • Palmerini, Emanuela;
    • Wainberg, Zev A.;
    • Desai, Jayesh;
    • Healey, John H.;
    • Sande, Michiel A. J.;
    • Bernthal, Nicholas M.;
    • Staals, Eric L.;
    • Peterfy, Charles G.;
    • Frezza, Anna Maria;
    • Hsu, Henry H.;
    • Wang, Qiang;
    • Shuster, Dale E.;
    • Stacchiotti, Silvia;
    • van de Sande, Michiel A J
    Publication type:
    journal article
    26
    27

    Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.

    Published in:
    Oncologist, 2024, v. 29, n. 11, p. 957, doi. 10.1093/oncolo/oyae210
    By:
    • Borazanci, Erkut H;
    • Bahary, Nathan;
    • Chung, Vincent;
    • Huyck, Timothy K;
    • Kio, Ebenezer A;
    • Chiorean, Elena Gabriela;
    • Skeel, Roland T;
    • Alese, Olatunji B;
    • Cardin, Dana B;
    • Fountzilas, Christos;
    • Hanna, Wahid T;
    • Leal, Alexis D;
    • Lee, Valerie;
    • Noonan, Anne M;
    • Philip, Philip A;
    • Wainberg, Zev A;
    • Pashova, Hristina;
    • Mann, Grace;
    • Oberstein, Paul E
    Publication type:
    Article
    28
    29
    30

    Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.

    Published in:
    Oncologist, 2021, v. 26, n. 3, p. e414, doi. 10.1002/onco.13623
    By:
    • Cascinu, Stefano;
    • Bodoky, György;
    • Muro, Kei;
    • Van Cutsem, Eric;
    • Oh, Sang Cheul;
    • Folprecht, Gunnar;
    • Ananda, Sumitra;
    • Girotto, Gustavo;
    • Wainberg, Zev A.;
    • Miron, Maria Luisa Limon;
    • Ajani, Jaffer;
    • Wei, Ran;
    • Liepa, Astra M.;
    • Carlesi, Roberto;
    • Emig, Michael;
    • Ohtsu, Atsushi
    Publication type:
    Article
    31

    Safety and Efficacy of Andecaliximab (GS‐5745) Plus Gemcitabine and Nab‐Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

    Published in:
    Oncologist, 2020, v. 25, n. 11, p. 954, doi. 10.1634/theoncologist.2020-0474
    By:
    • Bendell, Johanna;
    • Sharma, Sunil;
    • Patel, Manish R.;
    • Windsor, Kevin S.;
    • Wainberg, Zev A.;
    • Gordon, Michael;
    • Chaves, Jorge;
    • Berlin, Jordan;
    • Brachmann, Carrie Baker;
    • Zavodovskaya, Marianna;
    • Liu, JieJane;
    • Thai, Dung;
    • Bhargava, Pankaj;
    • Shah, Manish A.;
    • Khan, Saad A.;
    • Starodub, Alexander
    Publication type:
    Article
    32
    33

    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

    Published in:
    Oncologist, 2017, v. 22, n. 4, p. 375, doi. 10.1634/theoncologist.2016-0133
    By:
    • García‐Carbonero, Rocío;
    • van Cutsem, Eric;
    • Rivera, Fernando;
    • Jassem, Jacek;
    • Gore, Ira;
    • Tebbutt, Niall;
    • Braiteh, Fadi;
    • Argiles, Guillem;
    • Wainberg, Zev A.;
    • Funke, Roel;
    • Anderson, Maria;
    • McCall, Bruce;
    • Stroh, Mark;
    • Wakshull, Eric;
    • Hegde, Priti;
    • Ye, Weilan;
    • Chen, Daniel;
    • Chang, Ilsung;
    • Rhee, Ina;
    • Hurwitz, Herbert
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    Correction Notice
    47

    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    journal article
    48

    Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.

    Published in:
    British Journal of Cancer, 2019, v. 121, n. 4, p. 318, doi. 10.1038/s41416-019-0517-3
    By:
    • Veitch, Zachary W.;
    • Cescon, David W.;
    • Denny, Trisha;
    • Yonemoto, Lisa-Maria;
    • Fletcher, Graham;
    • Brokx, Richard;
    • Sampson, Peter;
    • Li, Sze-Wan;
    • Pugh, Trevor J.;
    • Bruce, Jeffrey;
    • Bray, Mark R.;
    • Slamon, Dennis J.;
    • Mak, Tak W.;
    • Wainberg, Zev A.;
    • Bedard, Philippe L.
    Publication type:
    Article
    49
    50